Former United States Securities and Exchange Commission attorney Willie Briscoe and the securities litigation firm of Powers Taylor, LLP are investigating the sale of IntegraMed America, Inc. (“IntegraMed” or “INMD”) (NASDAQ: INMD) to affiliates formed by Sagard Capital Partners, L.P. for shareholders. Under the proposed transaction, IntegraMed shareholders will only receive $14.05 in cash for each share of INMD stock owned, well below at least one analyst’s estimated value of $17.00 per share.
If you are an affected investor, and you want to learn more about the lawsuit or join the action, contact Zachary Groover at Powers Taylor, LLP, toll free (877) 728-9607, via e-mail at firstname.lastname@example.org, or Willie Briscoe at The Briscoe Law Firm, PLLC, (214) 706-9314, or via email at WBriscoe@TheBriscoeLawFirm.com. There is no cost or fee to you.
This cash transaction is valued at approximately $169.5 million and is expected to close no later than mid November 2012.
The investigation centers on whether IntegraMed shareholders are receiving adequate compensation for their shares in the buyout, whether the transaction undervalues IntegraMed stock, and whether IntegraMed’s board attempted to obtain the highest share price for all shareholders prior to agreeing to the deal. Notably, at least one analyst with Yahoo! Finance has estimated that the true inherent value of the company may be as high as $17.00 per share, well below the proposed sale price. “Due to the lack of a significant premium to the shareholders and other factors, we believe that the transaction may undervalue IntegraMed stock. Our lawsuit will seek to obtain the highest share price for all shareholders,” said shareholder rights attorney Willie Briscoe.The Briscoe Law Firm, PLLC is a full service business litigation and shareholder rights advocacy firm with more than 20 years of experience in complex litigation and transactional matters. Powers Taylor, LLP is a boutique litigation law firm that handles a variety of complex business litigation matters, including claims of investor and stockholder fraud, shareholder oppression, shareholder derivative suits, and security class actions.